Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06902779

Evaluation of the Impact of a Collaboration Between Hospital and Community Pharmacists at Hospital Discharge

The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. For community pharmacies, discharge prescriptions are often complex, and they sometimes lack the information that pharmacists need to deliver the treatment as safely as possible. As a result, there is a risk of medication errors, and a risk for patients. We aim to evaluate the benefits of this collaboration for adult patients admitted to the internal medicine ward of a regional hospital who are taking seven or more drugs and are being discharged to home.

The main question it aims to answer is : Does the enhanced collaboration reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions ? Researchers will compare patients when a hospital pharmacist is involved during the discharge process and when he or she is not involved, which corresponds to normal care.

The hospital pharmacist will not perform the intervention directly on the patient, but only with the community pharmacy. Once they agree to participate in the study, patients will only have to go to their usual community pharmacy after discharge and accept that the hospital transmits medical information to their usual pharmacy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Riviera-Chablais, Vaud-Valais

Rennaz, Canton of Vaud, 1847, Switzerland

Location status: Recruiting

Location contact

Paul Garin, PharmD

CONTACT

[email protected]

+41 79 534 21 36

Paul Garin, PharmD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients admitted to the internal medicine ward for more than 48 hours
  • Patients prescribed seven or more drugs at the time of screening
  • Patients discharged to home
  • Patients able to give informed consent as documented by signature

Exclusion criteria

  • Patient discharged to another hospital, nursing home or rehabilitation clinic
  • Refusal of the community pharmacy to participate
  • Inability to sign consent and follow the procedures of the study, due to language problems, psychological disorders, dementia, alterations of consciousness and lack of judgement

Treatment and study plan

Support of the hospital pharmacist for the medication management at hospital discharge

Other
  • The hospital pharmacist calls the community pharmacy the day before discharge to order unusual or specific medications 2) The day of discharge, the hospital pharmacist performs a medication reconciliation in collaboration with the hospital physician 3) Once completed, the discharge prescription is sent to the community pharmacy before the patient is discharged. 4) The hospital pharmacist calls the community pharmacy to provide additional information about the patient and the prescription and to answer any questions. Additional information will help the community pharmacist to understand the prescription : administrative data, clinical data, medication-related information, patient follow-up and patient concerns.

Primary outcomes

  1. Number of drug-related problems on the hospital discharge prescription

    Time frame: 7 days after hospital discharge

    Community pharmacists will assess the number of drug-related problems (DRP) on the discharge that they faced when preparing the discharge medication. They will have to use the PharmDISC system, which is a validated tool for referencing drug-related problems faced in the community which was adapted from the drug-related problems classification system of the Pharmaceutical Care Network Europe (PCNE). Community pharmacists will also document the intervention performed for each DRP, and the resolution (yes/no) of the DRP.

Secondary outcomes

  1. Patient's satisfaction

    Time frame: 7 days after hospital discharge

    Patients' satisfaction related to their visit at the pharmacy after hospital discharge will be assessed using a questionnaire. Patients will be contacted via email or telephone

  2. Community pharmacists' satisfaction

    Time frame: Through study completion, approximately 6 months

    The satisfaction of community pharmacists with the service provided by the hospital pharmacist at patient discharge will be evaluated

  3. 30 day readmission rate

    Time frame: 30 days after hospital discharge

    Number of participants with hospital emergency department visits and hospital readmission in the same hospital within 30 days of discharge

Study contacts

Contact information is provided by the study sponsor or research team.

Anne-Laure Blanc, PharmD, PhD

CONTACT

[email protected]

+41 58 773 45 43

Paul Garin, PharmD

CONTACT

[email protected]

+41 79 534 21 36

Sponsors and collaborators

Lead sponsor

Pharmacie des Hopitaux de l'Est Lemanique

Other

Registry information

Official study title

Enhanced Collaboration Between Hospital and Community Pharmacists to Improve the Hospital Discharge Process

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 30, 2025
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.